Key clinical point: There is no difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic renal cell cancer.
Major finding: At a mean follow-up of 11.7 months, the response rates were 33% for immunotherapy plus VEGF and 40% for ipilimumab/nivolumab. This difference was not statistically significant (between group difference, 7%; 95% confidence interval, –8% to 22%; P = .4).
Study details: Observational comparison of patient outcomes from the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) dataset.
Disclosures: Dr. Dudani had no financial disclosures.
Dudani, S. et al. Euro Onc 2019 Aug. 22. doi: 10.1016/j.eururo.2019.07.048.